Brian FinrowPreventive drugs may be the best solution to the antibiotic resistance crisisBy Brian Finrow│This piece was originally published at STAT NEWS on October 18, 2023Nov 9, 2023Nov 9, 2023
Brian FinrowCOVID drugs come in 3 flavors; it’s time for more diversityBy Brian Finrow │This piece was originally published at Drug Discovery & Development on October 12th, 2021Mar 23, 2023Mar 23, 2023
Brian FinrowDrug developers navigating ‘biology’s century’ need a model. We made oneBy Brian Finrow, Aleks Engel and Srinivas Akkaraju │This piece was originally published at STAT NEWS on March 15th, 2023Mar 20, 2023Mar 20, 2023
Brian FinrowMoving closer to the patientThoughts on the journey from bench to bedside for patients at risk of C. difficile infectionApr 18, 2022Apr 18, 2022
Brian Finrow‘You can’t get there from here:’ Birth of a biotech platformLumen’s new paper in Nature Biotechnology describes how it harnessed spirulina as a factory and delivery vehicle for oral protein…Mar 23, 2022Mar 23, 2022
Brian FinrowIntranasal passive vaccines: thinking beyond the jabThoughts on Lumen’s new collaboration to fight flu with inhaled antibodiesFeb 1, 2022Feb 1, 2022
Brian FinrowAntibody synergyA new tool for making high-potency antibody drugsDec 24, 2021Dec 24, 2021
Brian FinrowCovid therapies must look beyond the lungsThe “respiratory” disease strikes many organ systems, including the GI tract. Lumen is testing the world’s first oral therapy directed at…Oct 6, 2021Oct 6, 2021
Brian FinrowMachine learning meets molecular farmingHow Google’s AI experts are helping advance Lumen Bio’s unique biologics platformAug 11, 2021Aug 11, 2021
Brian FinrowThe ideal platform to fight a silent pandemicReflecting on Lumen’s new collaboration with Novo NordiskJun 16, 2021Jun 16, 2021
